Drugs / QR-504a
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05052554 | Aug 2021 → Apr 2022 | corneal dystrophy, Fuchs endothelial, 3 | ProQR Therapeutics | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QR-504a | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05052554 ↗ |
| Route | Intravitreal | “administered intravitreally in Eye 2” NCT05052554 ↗ |